Q2V905
PR
Gene name |
TFRC |
Protein name |
Transferrin receptor protein 1 |
Names |
|
Species |
Equus caballus (Horse) |
KEGG Pathway |
ecb:100034089 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q2V905
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q2V905-F1 | Predicted | AlphaFoldDB |
39 variants for Q2V905
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3446480540 | 15 | A>E | No | EVA | |
| rs3446511631 | 47 | V>A | No | EVA | |
| rs3446409528 | 93 | R>G | No | EVA | |
| rs3445906799 | 98 | S>T | No | EVA | |
| rs3446480193 | 185 | N>S | No | EVA | |
| rs3445907049 | 191 | E>Q | No | EVA | |
| rs3446329733 | 200 | G>D | No | EVA | |
| rs3446024221 | 284 | V>I | No | EVA | |
| rs3438728597 | 292 | Q>K | No | EVA | |
| rs3447606440 | 293 | A>T | No | EVA | |
| rs3446241776 | 301 | N>D | No | EVA | |
| rs3445675862 | 301 | N>K | No | EVA | |
| rs3446352221 | 303 | P>S | No | EVA | |
| rs3446447361 | 304 | V>F | No | EVA | |
| rs3439223785 | 307 | H>Y | No | EVA | |
| rs3446279656 | 332 | Q>R | No | EVA | |
| rs3446495933 | 351 | A>E | No | EVA | |
| rs3446447408 | 351 | A>T | No | EVA | |
| rs3445907132 | 385 | N>S | No | EVA | |
| rs3445907028 | 387 | E>V | No | EVA | |
| rs3445675624 | 392 | R>K | No | EVA | |
| rs3446425749 | 394 | F>L | No | EVA | |
| rs3446623881 | 396 | V>I | No | EVA | |
| rs3446480378 | 404 | E>V | No | EVA | |
| rs3445676116 | 456 | V>I | No | EVA | |
| rs3446425735 | 461 | G>S | No | EVA | |
| rs3446280208 | 467 | A>S | No | EVA | |
| rs3446480534 | 468 | I>V | No | EVA | |
| rs3439333608 | 473 | W>W | No | EVA | |
| rs3439301994 | 479 | S>N | No | EVA | |
| rs3446410077 | 494 | A>F | No | EVA | |
| rs3446480640 | 494 | A>V | No | EVA | |
| rs3439282138 | 583 | L>V | No | EVA | |
| rs395605923 | 596 | A>K | No | EVA | |
| rs3445675488 | 634 | Q>K | No | EVA | |
| rs3445676001 | 641 | E>V | No | EVA | |
| rs782900561 | 666 | D>V | No | EVA | |
| rs3446280154 | 672 | R>F | No | EVA | |
| rs3446023850 | 694 | S>V | No | EVA |
No associated diseases with Q2V905
11 GO annotations of cellular component
| Name | Definition |
|---|---|
| basolateral plasma membrane | The region of the plasma membrane that includes the basal end and sides of the cell. Often used in reference to animal polarized epithelial membranes, where the basal membrane is the part attached to the extracellular matrix, or in plant cells, where the basal membrane is defined with respect to the zygotic axis. |
| clathrin-coated pit | A part of the endomembrane system in the form of an invagination of a membrane upon which a clathrin coat forms, and that can be converted by vesicle budding into a clathrin-coated vesicle. Coated pits form on the plasma membrane, where they are involved in receptor-mediated selective transport of many proteins and other macromolecules across the cell membrane, in the trans-Golgi network, and on some endosomes. |
| early endosome | A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways. |
| endosome membrane | The lipid bilayer surrounding an endosome. |
| external side of plasma membrane | The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface. |
| extracellular exosome | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. |
| HFE-transferrin receptor complex | A protein complex containing at least HFE and a transferrin receptor (either TFR1/TFRC or TFR2), proposed to play a role in the sensing of transferrin-bound Fe (Fe2-Tf) on the plasma membrane to regulate hepcidin transcription. |
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| melanosome | A tissue-specific, membrane-bounded cytoplasmic organelle within which melanin pigments are synthesized and stored. Melanosomes are synthesized in melanocyte cells. |
| perinuclear region of cytoplasm | Cytoplasm situated near, or occurring around, the nucleus. |
| recycling endosome | An organelle consisting of a network of tubules that functions in targeting molecules, such as receptors transporters and lipids, to the plasma membrane. |
5 GO annotations of molecular function
| Name | Definition |
|---|---|
| double-stranded RNA binding | Binding to double-stranded RNA. |
| protein homodimerization activity | Binding to an identical protein to form a homodimer. |
| protein kinase binding | Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. |
| protein-containing complex binding | Binding to a macromolecular complex. |
| transferrin receptor activity | Combining selectively with transferrin, and delivering transferrin into the cell via endocytosis. Transferrin is a major iron carrier protein in vertebrates. |
19 GO annotations of biological process
| Name | Definition |
|---|---|
| cellular iron ion homeostasis | Any process involved in the maintenance of an internal steady state of iron ions at the level of a cell. |
| cellular response to leukemia inhibitory factor | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leukemia inhibitory factor stimulus. |
| cellular response to xenobiotic stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. |
| intracellular signal transduction | The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell. |
| iron ion transport | The directed movement of iron (Fe) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| negative regulation of apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| negative regulation of mitochondrial fusion | Any process that decreases the frequency, rate or extent of merging of two or more mitochondria within a cell to form a single compartment. |
| osteoclast differentiation | The process in which a relatively unspecialized monocyte acquires the specialized features of an osteoclast. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue. |
| positive regulation of B cell proliferation | Any process that activates or increases the rate or extent of B cell proliferation. |
| positive regulation of bone resorption | Any process that activates or increases the frequency, rate or extent of bone resorption. |
| positive regulation of I-kappaB kinase/NF-kappaB signaling | Any process that activates or increases the frequency, rate or extent of I-kappaB kinase/NF-kappaB signaling. |
| positive regulation of isotype switching | Any process that activates or increases the frequency, rate or extent of isotype switching. |
| positive regulation of NF-kappaB transcription factor activity | Any process that activates or increases the frequency, rate or extent of activity of the transcription factor NF-kappaB. |
| positive regulation of peptidyl-serine phosphorylation | Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-serine. |
| positive regulation of protein localization to nucleus | Any process that activates or increases the frequency, rate or extent of protein localization to nucleus. |
| positive regulation of protein-containing complex assembly | Any process that activates or increases the frequency, rate or extent of protein complex assembly. |
| positive regulation of T cell proliferation | Any process that activates or increases the rate or extent of T cell proliferation. |
| receptor internalization | A receptor-mediated endocytosis process that results in the movement of receptors from the plasma membrane to the inside of the cell. The process begins when cell surface receptors are monoubiquitinated following ligand-induced activation. Receptors are subsequently taken up into endocytic vesicles from where they are either targeted to the lysosome or vacuole for degradation or recycled back to the plasma membrane. |
| transferrin transport | The directed movement of transferrin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
3 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9MYZ3 | TFRC | Transferrin receptor protein 1 | Felis catus (Cat) (Felis silvestris catus) | PR |
| Q9GLD3 | TFRC | Transferrin receptor protein 1 | Canis lupus familiaris (Dog) (Canis familiaris) | PR |
| Q62351 | Tfrc | Transferrin receptor protein 1 | Mus musculus (Mouse) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MDQARSAFSN | LFGGAPLSYT | RFSLARQVDG | DNSHVEMKLA | VDEEENVDNN | VRSNHASLTK |
| 70 | 80 | 90 | 100 | 110 | 120 |
| PKRFNGSFCY | AVIAVIIFFL | IGFMIGYLGY | CKRVEPKSEC | GRSGDSKEIE | GTEPPETEEY |
| 130 | 140 | 150 | 160 | 170 | 180 |
| FPETPSRLLW | TDLRTMLSER | LTATEFTNTI | KRLNGNSYVP | REAGSQKDES | LAFFIENQFR |
| 190 | 200 | 210 | 220 | 230 | 240 |
| EFKLNKVWRD | EHFVKIQVKG | SNAQSSVTVV | NGSGDMISLV | ENPTGYVAYS | KATTVTGKLV |
| 250 | 260 | 270 | 280 | 290 | 300 |
| HANFGTKEDY | EALSYPVNGS | LVIVRAGEIT | FAQKVANAES | LNAVGVLIYM | DQAKFPIVNA |
| 310 | 320 | 330 | 340 | 350 | 360 |
| NLPVFGHAHL | GTGDPYTPGF | PSFNHTQFPP | SQSSGLPNIP | VQTISRAAAE | ALFANMKGDC |
| 370 | 380 | 390 | 400 | 410 | 420 |
| PSSWKTDSSC | RLEFPGDKNV | KLTVNNELKE | IRIFNVFGVI | KGFEEPDRYV | VIGAQRDAWG |
| 430 | 440 | 450 | 460 | 470 | 480 |
| PGAAKSSVGT | ALLLELARIF | SDMVSKGGFK | PSRSIVFASW | GAGDFGAIGA | TEWLEGYLSS |
| 490 | 500 | 510 | 520 | 530 | 540 |
| LHLKAFTYIN | LDKAVLGAKN | FKVSASPLLY | SLIEKTMQEV | KHPVTGLSLY | RDSNWINKVE |
| 550 | 560 | 570 | 580 | 590 | 600 |
| KLSFDNAAFP | FLAYSGIPAL | SFCFCEDTEY | PYLGTTMDTY | EVLSQNVPEL | SRLTRAAAEV |
| 610 | 620 | 630 | 640 | 650 | 660 |
| AGQLLIKLSY | DVELNLNYDM | YNDKILSFVK | DMNQFRADIK | EMGLNLQWLY | SARGDFFRAT |
| 670 | 680 | 690 | 700 | 710 | 720 |
| SRLTTDYKNA | ERANRVVMRE | INDRIMKVEY | HFLSPYVSPR | ESPFRHIFWG | SGSHTLSALL |
| 730 | 740 | 750 | 760 | ||
| EHLKLRQKNS | GAFNETLLRN | QLALATWTIQ | GAANALSGDI | WDIDNEF |